TP53 and B-cell chronic lymphocytic leukemia: Similar to the management of most malignancy, the most suitable treatment for a patient with CLL is selected based on genetic features of the disease itself—the presence of a P53 mutation or 17p deletion and the mutational state of the IGHV—and patient factors [35].